Yan, Tristan D. and Deraco, Marcello and Baratti, Dario and Kusamura, Shigeki and Elias, Dominique and Glehen, Olivier and Gilly, Francois N. and Levine, Edward A. and Shen, Perry and Mohamed, Faheez and Moran, Brendan J. and Morris, David L. and Chua, Terence C. and Piso, Pompiliu and Sugarbaker, Paul H. (2009) Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. JOURNAL OF CLINICAL ONCOLOGY, 27 (36). pp. 6237-6242. ISSN 0732-183X, 1527-7755
Full text not available from this repository. (Request a copy)Abstract
Purpose This multi-institutional registry study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM). Patients and Methods A multi-institutional data registry that included 405 patients with DMPM treated by a uniform approach that used CRS and HIPEC was established. The primary end point was overall survival. The secondary end point was evaluation of prognostic variables for overall survival. Results Follow-up was complete in 401 patients (99%). The median follow-up period for the patients who were alive was 33 months (range, 1 to 235 months). The mean age was 50 years (standard deviation [SD], 14 years). Three hundred eighteen patients (79%) had epithelial tumors. Twenty-five patients (6%) had positive lymph nodes. The mean peritoneal cancer index was 20. One hundred eighty-seven patients (46%) had complete or near-complete cytoreduction. Three hundred seventy-two patients (92%) received HIPEC. One hundred twenty-seven patients (31%) had grades 3 to 4 complications. Nine patients (2%) died perioperatively. The mean length of hospital stay was 22 days (SD, 15 days). The overall median survival was 53 months (1 to 235 months), and 3- and 5-year survival rates were 60% and 47%, respectively. Four prognostic factors were independently associated with improved survival in the multivariate analysis: epithelial subtype (P < .001), absence of lymph node metastasis (P < .001), completeness of cytoreduction scores of CC-0 or CC-1 (P < .001), and HIPEC (P < .002). Conclusion The data suggest that CRS combined with HIPEC achieved prolonged survival in selected patients with DMPM.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | REGIONAL HYPERTHERMIA; CISPLATIN; PERFUSION; ASBESTOS; THERAPY; CANCER; TRIAL; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Chirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 27 Aug 2020 08:35 |
| Last Modified: | 27 Aug 2020 08:35 |
| URI: | https://pred.uni-regensburg.de/id/eprint/27966 |
Actions (login required)
 |
View Item |
